Serous Retinopathy Associated With Combination MEK and Fibroblast Growth Factor Receptor Inhibitor.
| Autor: | Day HR Jr; Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA., Finn AP; Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of vitreoretinal diseases [J Vitreoretin Dis] 2023 Apr 10; Vol. 7 (4), pp. 352-355. Date of Electronic Publication: 2023 Apr 10 (Print Publication: 2023). |
| DOI: | 10.1177/24741264231163393 |
| Abstrakt: | Purpose: To present a case of a chemotherapy regimen combining a fibroblast growth factor receptor (FGFR) and mitogen-activated protein kinase kinase (MEK) inhibitor leading to serous retinopathy. Methods: A retrospective chart review of a single case was performed. Results: A 67-year-old man with pancreatic and prostate cancer developed bilateral multifocal pockets of subretinal fluid while on an experimental chemotherapy regimen combining an MEK inhibitor (trametinib) and an FGFR inhibitor (erdafitinib). Conclusions: Given that FGFR lies upstream to the mitogen-activated protein kinase signaling pathway, retinal toxicity may be more severe and more common with FGFR-MEK combination therapy. Future studies are necessary to guide ophthalmic surveillance. Competing Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Finn is on the advisory boards of Allergan, EyePoint, Iveric Bio, and Alimera and is a consultant to Genentech. (© The Author(s) 2023.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|